================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2009
ONCOLOGIX TECH, INC.
---------------------------------------------------------
(Name of Small Business Issuer as Specified in Its Charter)
0-15482
----------------------
(Commission File Number)
Nevada 86-1006416
------------------------------ -----------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
P.O. Box 8832
Grand Rapids, MI 49518-8832
--------------------------------------
(Address of principal executive offices)
(616) 977-9933
-------------------------
(Issuer's telephone number)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 8.01 - Other Events
During April 2009, the Company's Board of Directors authorized the
management of the Company to offer holders of convertible promissory notes,
payment of which were then overdue, a reduction in the conversion price of those
convertible promissory notes to $0.05 per common share in consideration of an
immediate conversion of the notes to common stock, or, in the alternative, the
ability to extend the due dates of the convertible promissory notes. In August
2009, the Company completed the issuance of securities related to these note
conversions. The Company issued 30,921,961 shares of common stock, valued at
$0.05 per share, in full payment of $1,403,821.90 in the aggregate principal
amount of the notes and the aggregate amount of $142,276.18 accrued interest to
35 holders of convertible promissory notes. In addition, three note holders
agreed to extend their convertible promissory notes and the effects of those
extensions are reflected in the table below.
After giving effect to the conversion of those notes and extension of the
due dates of those notes that were not converted, the Company currently has
outstanding convertible promissory notes in the aggregate amount of $1,589,390
in principal and interest due as outlined in the table below.
Note Due Dates Principal and Interest Due
-------------- --------------------------
December 4, 2008 (1) $ 137,500
September 2009 (2) $ 1,173,828
January 2010 (3) 33,000
March 2012 (4) 3,037
March 2012 (5) 242,025
-----------
Total $ 1,589,390
===========
(1) Convertible promissory note, bearing interest at 8% per annum,
includes accrued interest of approximately $12,500 as of the date of
this report. Investor indicated verbally intention to extend but has
not completed paperwork.
(2) Convertible promissory notes, bearing interest at 6% per annum, due
September 17, 2009. Includes accrued interest in the amount of $83,828
as of the due dates of the notes.
(3) Convertible promissory note, bearing interest at 6% per annum, due
January 22, 2010. Includes accrued interest of approximately $3,000 as
of the date of this report.
(4) Convertible promissory note, bearing interest at 6% per annum due
March 31, 2012. Includes accrued interest of approximately $325 as of
the date of this report.
(5) Convertible promissory note, bearing interest at 6% per annum, due
March 31, 2012. Includes accrued interest of approximately $7,000 as
of the date of this report. Note issued in settlement of accrued
salary for former President.
The Company will be addressing the notes due in September 2009 during the
next month and a half.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Dated: August 14, 2009 ONCOLOGIX TECH, INC.
By: /s/ Anthony Silverman
--------------------------------
Anthony Silverman,
Chief Executive Officer
and President
By: /s/ Michael A. Kramarz
--------------------------------
Michael A. Kramarz,
Chief Financial Officer